Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can Praxbind Push Pradaxa Ahead?

This article was originally published in The Pink Sheet Daily

Executive Summary

Approval of antidote should give Boehringer Ingelheim’s anticoagulant a needed advantage in a tough market, but it has a short window before Portola’s Factor Xa antidote comes along.

Advertisement

Related Content

Portola Finally Gets FDA OK For Factor Xa Antidote AndexXa
Portola May Need Randomized Trial For AndexXa Approval. The Question Is When
Portola Seeks Narrower Label For AndexXa Antidote After FDA Rebuff
Portola Seeks Narrower Label For AndexXa Antidote After FDA Rebuff
Boehringer Avoids Pradaxa Trial, Board Chair Deposition With $650 Mil. Settlement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077883

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel